Vi­for blasts FDA's 'reck­less' re­nam­ing of 4 drugs un­der the same mol­e­cule moniker

Out­side of the FDA’s de­ci­sion to add four-let­ter, mean­ing­less suf­fix­es on the end of non­pro­pri­etary names for bi­o­log­ics, the nam­ing of phar­ma­ceu­ti­cals has not been a con­tro­ver­sial task in re­cent years.

But in a new cit­i­zen pe­ti­tion filed ear­li­er this month, Switzer­land’s Vi­for Phar­ma is rais­ing con­cerns with the FDA’s de­ci­sion to change its Or­ange Book so the ac­tive in­gre­di­ents of four drugs, in­clud­ing three com­plex IV iron prod­ucts and Vi­for’s chron­ic kid­ney dis­ease drug Velphoro, were lumped un­der the same name of “fer­ric oxy­hy­drox­ide.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.